Alkermes Hits Two-Year Low On Depression Drug Failure
Shares of drugmaker Alkermes (ALKS) plunged Thursday after the company’s depression drug failed two late-stage trials, though the company claimed it still saw positive signals. Alkermes ran two clinical trials, Forward-3 and Forward-4, comparing its drug ALKS 5461 to a placebo at two dose levels, 2mg and 0.5mg. Neither achieved its endpoint of statistically significant improvement based on the Montgomery — Asberg Depression Rating Scale (MADRS)